Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Best practices for companion diagnostic and therapeutic development: translating between the stakeholders.

Love D, Stratton E, Stocum M.

N Biotechnol. 2012 Sep 15;29(6):689-94. doi: 10.1016/j.nbt.2012.06.005. Review.

PMID:
22743138
2.

Do companion diagnostics make economic sense for drug developers?

Agarwal A.

N Biotechnol. 2012 Sep 15;29(6):695-708. doi: 10.1016/j.nbt.2012.04.004. Review.

PMID:
22575210
3.

US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics.

Philip R, Carrington L, Chan M.

Bioanalysis. 2011 Feb;3(4):383-9. doi: 10.4155/bio.11.1.

PMID:
21338257
4.

The biomarker is not the end.

Nohaile M.

Drug Discov Today. 2011 Oct;16(19-20):878-83. doi: 10.1016/j.drudis.2011.08.011. Review.

PMID:
21888986
5.
6.

Predictive markers in early research and companion diagnostic developments in oncology.

Pickl M, Ruge E, Venturi M.

N Biotechnol. 2012 Sep 15;29(6):651-5. doi: 10.1016/j.nbt.2012.03.008. Review.

PMID:
22484859
7.

Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals.

Roscoe DM, Hu YF, Philip R.

Expert Rev Mol Diagn. 2015;15(7):869-80. doi: 10.1586/14737159.2015.1045490. Review.

PMID:
26109316
8.

[Diagnostic kits in parasitology: which controls?].

Rossi P.

Parassitologia. 2004 Jun;46(1-2):145-9. Review. Italian.

PMID:
15305705
9.

A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.

Luo D, Smith JA, Meadows NA, Schuh A, Manescu KE, Bure K, Davies B, Horne R, Kope M, DiGiusto DL, Brindley DA.

Front Genet. 2016 Jan 28;6:357. doi: 10.3389/fgene.2015.00357. Erratum in: Front Genet. 2016;7:104.

10.

Molecular tools for companion diagnostics.

Zieba A, Grannas K, Söderberg O, Gullberg M, Nilsson M, Landegren U.

N Biotechnol. 2012 Sep 15;29(6):634-40. doi: 10.1016/j.nbt.2012.05.004. Review.

PMID:
22634023
11.

Evaluating the value of genomic diagnostics: implications for clinical practice and public policy.

Issa AM.

Adv Health Econ Health Serv Res. 2008;19:191-206. Review.

PMID:
19548519
12.
13.

Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.

[No authors listed]

BioDrugs. 2003;17(1):69-72.

PMID:
12534322
14.

The current and future state of companion diagnostics.

Agarwal A, Ressler D, Snyder G.

Pharmgenomics Pers Med. 2015 Mar 31;8:99-110. doi: 10.2147/PGPM.S49493. Review.

15.

Personalized medicine: elusive dream or imminent reality?

Lesko LJ.

Clin Pharmacol Ther. 2007 Jun;81(6):807-16.

PMID:
17505496
16.

Translational research: precision medicine, personalized medicine, targeted therapies: marketing or science?

Marquet P, Longeray PH, Barlesi F; participants of round table N°1 of Giens XXX:., Ameye V, Augé P, Cazeneuve B, Chatelut E, Diaz I, Diviné M, Froguel P, Goni S, Gueyffier F, Hoog-Labouret N, Mourah S, Morin-Surroca M, Perche O, Perin-Dureau F, Pigeon M, Tisseau A, Verstuyft C.

Therapie. 2015 Jan-Feb;70(1):1-19. doi: 10.2515/therapie/2014231. English, French.

PMID:
25679189
17.

Point-of-care diagnostics: will the hurdles be overcome this time?

Huckle D.

Expert Rev Med Devices. 2006 Jul;3(4):421-6. Review.

PMID:
16866639
18.

Considerations for the successful co-development of targeted cancer therapies and companion diagnostics.

Fridlyand J, Simon RM, Walrath JC, Roach N, Buller R, Schenkein DP, Flaherty KT, Allen JD, Sigal EV, Scher HI.

Nat Rev Drug Discov. 2013 Oct;12(10):743-55. doi: 10.1038/nrd4101.

PMID:
24008432
19.

New ways of insulin delivery.

Heinemann L.

Int J Clin Pract Suppl. 2011 Feb;(170):31-46. doi: 10.1111/j.1742-1241.2010.02577.x. Review.

PMID:
21323811
20.

The clinical benefits, ethics, and economics of stratified medicine and companion diagnostics.

Trusheim MR, Berndt ER.

Drug Discov Today. 2015 Dec;20(12):1439-50. doi: 10.1016/j.drudis.2015.10.017. Review.

PMID:
26542060
Items per page

Supplemental Content

Support Center